Language selection

Search


Guidance document : regulatory requirements for drug identification numbers (DINs).H164-273/2024E-PDF

"When Health Canada authorizes a drug to be marketed in Canada, a Drug Identification Number (DIN) is issued to the manufacturer and printed on the package labels. A DIN indicates that the evaluation of the drug determined that it met the relevant requirements of the Food and Drugs Act and its Regulations and the drug has a favourable risk/benefit profile. Manufacturers of prescription and non-prescription drugs must obtain a DIN before they are marketed in Canada. Market authorization of a drug may require the additional issuance of a Notice of Compliance (NOC)"--Introduction, page 9.

Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.936452&sl=0

Publication information
Department/Agency
  • Canada. Health Canada, issuing body.
TitleGuidance document : regulatory requirements for drug identification numbers (DINs).
Publication typeMonograph
Language[English]
Other language editions[French]
Later editionGuidance document : [2024/07/15 edition]
Earlier editionGuidance document : [2021/06/28 edition]
FormatDigital text
Electronic document
Note(s)
  • Cover title.
  • "Administrative changes date: 2024/05/01."
  • Issued also in French under title: Ligne directrice : exigences réglementaires associées à une identification numérique attribuée à une drogue (DIN).
Publishing information
  • Ottawa, Ontario : Health Canada = Santé Canada, May 2024.
  • ©2024
Description1 online resource (33 pages)
ISBN9780660712284
Catalogue number
  • H164-273/2024E-PDF
Departmental catalogue number240028
Edition
  • [2024/05/01 edition].
Subject terms
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.

Page details